These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20978949)

  • 1. Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients.
    Kossoff EB; Ngamphaiboon N; Laudico TJ; O'Connor TL
    Med Oncol; 2011 Dec; 28 Suppl 1():S115-20. PubMed ID: 20978949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
    J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
    J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Egerton N
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
    Valero V; Vrdoljak E; Xu B; Thomas E; Gómez H; Manikhas A; Medina C; Li RK; Ro J; Bosserman L; Vahdat L; Mukhopadhyay P; Opatt D; Sparano JA
    Clin Breast Cancer; 2012 Aug; 12(4):240-6. PubMed ID: 22658378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
    Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
    Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative dosing schedules and administration updates for ixabepilone.
    Kossoff E
    J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing ixabepilone adverse events with dose reduction.
    Valero V
    Clin Breast Cancer; 2013 Feb; 13(1):1-6. PubMed ID: 23098573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
    Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD
    Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
    J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
    Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
    J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Luu T; Kim KP; Blanchard S; Anyang B; Hurria A; Yang L; Beumer JH; Somlo G; Yen Y
    Breast Cancer Res Treat; 2018 Jan; 167(2):469-478. PubMed ID: 28956187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
    Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
    J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.